Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.

US-based genomic medicine developer Ensoma launched on Thursday with $70m in series A financing provided by investors including pharmaceutical firm Takeda and life sciences real estate investment trust Alexandria Real Estate Equities. 5AM Ventures led the round, which also included financial services group Fidelity‚Äôs F-Prime Capital unit, Viking Global Investors, Cormorant Asset Management, RIT Capital…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.